KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $3.4 million.

  • Rigel Pharmaceuticals' Share-based Compensation rose 27.19% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 1.54%. This contributed to the annual value of $12.4 million for FY2024, which is 40.73% up from last year.
  • Rigel Pharmaceuticals' Share-based Compensation amounted to $3.4 million in Q3 2025, which was up 2.66% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Share-based Compensation peaked at $5.1 million during Q1 2024, and registered a low of $1.9 million during Q4 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $2.6 million (2024), whereas its average is $2.8 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Share-based Compensation plummeted by 52.62% in 2023 and then surged by 86.15% in 2024.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Share-based Compensation stood at $2.3 million in 2021, then surged by 74.43% to $4.1 million in 2022, then tumbled by 52.62% to $1.9 million in 2023, then increased by 7.97% to $2.1 million in 2024, then rose by 27.19% to $3.4 million in 2025.
  • Its Share-based Compensation was $3.4 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.3 million in Q1 2025.